Nuvalent Inc

GSK is expected to report a 97.3% year-over-year decline in earnings per share when it releases second-quarter results on Tuesday before the market opens. The consensus EPS estimate stands at $1.25, while revenue is forecast to rise 37.4% to $10.98 billion. The company’s Specialty Medicines unit, which includes respiratory, immunology and inflammation, oncology, and HIV, is projected to deliver double-digit sales growth across all therapy areas, though generic competition for certain legacy products may pose a headwind. On the same day, CEO Luke Miels will host an “Accelerate Growth” event where he is expected to outline his strategy, with analysts at UBS focusing on whether he can provide a credible path to achieving the sales target of more than £40 billion by 2031 and an update on pipeline reprioritization following the acquisition of Nuvalent.

Brodsky & Smith is investigating the boards of Personalis, Distribution Solutions Group, Cross Country Healthcare, Nuvalent, and Dana Incorporated for potential fiduciary duty breaches in connection with their proposed acquisitions. Personalis is being acquired by Tempus AI for $16.25 per share, representing a total enterprise value of $1.5 billion net of Tempus’ existing ownership. Distribution Solutions Group is being acquired by LKCM Headwater Investments for $35.00 per share in cash, with LKCM Headwater and its affiliates already owning approximately 79% of the company’s outstanding common stock. Cross Country Healthcare is being acquired by Knox Lane for $13.25 per share in an all-cash transaction valued at $437 million. Nuvalent is being acquired by GSK for $124.00 per share in cash in a deal valued at $10.6 billion. Dana is being acquired by Eaton in a transaction valued at approximately $5.1 billion, where Eaton shareholders will own at least 50.1% and Dana shareholders approximately 49.9% of the combined company at close, and Eaton will receive a cash distribution of approximately $1.1 billion. The investigations focus on whether the boards failed to conduct a fair process and whether the proposed transactions pay fair value to shareholders.

Halper Sadeh LLC, an investor rights law firm, is investigating whether the proposed transactions involving Dana Incorporated, Element Solutions Inc, Nuvalent Inc, and Boundless Bio Inc are fair to their shareholders. The firm is examining Dana's sale to Eaton Corporation, where Dana shareholders would own approximately 49.9% of the combined company, and Element Solutions' sale to Solstice Advanced Materials for $10.00 in cash and 0.500 shares of Solstice common stock per Element share, with Element shareholders expected to own about 44% of the combined entity. It is also looking into Nuvalent's sale to GSK for $124.00 per share in cash and Boundless Bio's merger with Serapha Bio, where Boundless Bio shareholders would hold roughly 3.7% of the combined company. Halper Sadeh may seek increased consideration or additional disclosures on behalf of shareholders, who can contact the firm at no cost to discuss their legal rights.

Halper Sadeh LLC, an investor rights law firm, is investigating LCI Industries, Nuvalent, Dana Incorporated, and Taylor Morrison Home Corporation for potential violations of federal securities laws or breaches of fiduciary duties to shareholders in connection with their proposed sales. The firm is examining LCI Industries' sale to Patrick Industries for 1.2440 shares of Patrick common stock per LCI share, Nuvalent's sale to GSK for $124.00 per share in cash, Dana's sale to Eaton Corporation where Dana shareholders would own approximately 49.9% of the combined company, and Taylor Morrison's sale to Berkshire Hathaway for $72.50 per common share in cash. Halper Sadeh LLC may seek increased consideration, additional disclosures, or other relief on behalf of shareholders, and encourages them to contact the firm to discuss their rights at no cost.

Brodsky & Smith is investigating the boards of Arcosa, Fathom Holdings, Nuvalent, and Dana Incorporated over potential fiduciary duty breaches in their respective merger agreements. Arcosa is being acquired by CRH for $150.00 per share in cash, with a total enterprise value of approximately $8.5 billion. Fathom Holdings is being acquired by Bed Bath & Beyond in a deal implying an equity value of about $53.38 million, with an exchange ratio of 0.2236 Bed Bath & Beyond shares per Fathom share. Nuvalent is being acquired by GSK for $124.00 per share in cash in a deal valued at $10.6 billion. Dana is being acquired by Eaton Corporation in a transaction valued at approximately $5.1 billion, where Eaton shareholders will own at least 50.1% and Dana shareholders approximately 49.9% of the combined company, and Eaton will receive a cash distribution of about $1.1 billion.

Monteverde & Associates PC, a class action law firm, is investigating four proposed mergers. The firm is looking into Pacific Financial Corporation's merger with Banner Corporation, where Pacific Financial shareholders are expected to receive 0.2633 share of Banner common stock for each share held, with a shareholder vote scheduled for August 12, 2026. It is also investigating Nuvalent, Inc.'s sale to GSK plc for $124.00 per share in cash, Cross Country Healthcare, Inc.'s sale to KL Criss Cross Intermediate, LLC for $13.25 per share in cash with a shareholder vote set for July 16, 2026, and Bio Green Med Solution, Inc.'s merger with Future NRG Sdn. Bhd.

Halper Sadeh LLC, an investor rights law firm, is investigating whether the proposed sales of Open Lending Corporation, Nuvalent Inc., Organon & Co., and SUNation Energy Inc. are fair to shareholders. The firm is examining Open Lending's sale to ANV Group Holdings Ltd. for $3.15 per share, Nuvalent's sale to GSK plc for $124.00 per share in cash, Organon's sale to Sun Pharmaceutical Industries Limited for $14.00 per share, and SUNation Energy's merger with Suniva, in which SUNation shareholders would own approximately 1.8% of the combined company. Halper Sadeh LLC may seek increased consideration, additional disclosures, or other relief on behalf of shareholders, and encourages investors to contact the firm to discuss their rights at no cost.